What is Zacks Research’s Forecast for Medifast Q2 Earnings?

Medifast Inc (NYSE:MED) – Zacks Research dropped their Q2 2026 earnings per share estimates for shares of Medifast in a note issued to investors on Monday, May 25th. Zacks Research analyst Team now forecasts that the specialty retailer will earn ($0.68) per share for the quarter, down from their previous estimate of ($0.42). The consensus estimate for Medifast’s current full-year earnings is ($2.00) per share. Zacks Research also issued estimates for Medifast’s Q3 2026 earnings at ($0.60) EPS, Q4 2026 earnings at ($0.50) EPS, FY2026 earnings at ($1.97) EPS, Q1 2027 earnings at ($0.17) EPS, Q2 2027 earnings at ($0.66) EPS, Q3 2027 earnings at ($0.58) EPS, Q4 2027 earnings at ($0.48) EPS, FY2027 earnings at ($1.89) EPS, Q1 2028 earnings at ($0.15) EPS and FY2028 earnings at ($1.81) EPS.

Several other analysts have also weighed in on MED. Stephens decreased their price target on Medifast from $15.00 to $12.00 and set an “equal weight” rating on the stock in a report on Thursday, February 19th. Weiss Ratings lowered Medifast from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, May 6th. Finally, Wall Street Zen upgraded Medifast from a “sell” rating to a “hold” rating in a report on Saturday, March 21st. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Reduce” and an average price target of $12.00.

Medifast Stock Performance

NYSE:MED opened at $12.66 on Thursday. The stock’s fifty day moving average is $11.16 and its 200 day moving average is $11.12. Medifast has a fifty-two week low of $9.22 and a fifty-two week high of $15.46. The firm has a market capitalization of $140.77 million, a PE ratio of -6.92 and a beta of 0.55.

Medifast (NYSE:MED) last released its quarterly earnings results on Monday, May 4th. The specialty retailer reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.55) by $0.36. Medifast had a negative return on equity of 4.80% and a negative net margin of 5.78%.The company had revenue of $76.04 million for the quarter, compared to analyst estimates of $69.20 million. Medifast has set its FY 2026 guidance at -2.750–1.550 EPS and its Q2 2026 guidance at -1.000–0.500 EPS.

Institutional Trading of Medifast

Several institutional investors and hedge funds have recently made changes to their positions in the business. Empowered Funds LLC lifted its position in shares of Medifast by 59.9% during the first quarter. Empowered Funds LLC now owns 71,584 shares of the specialty retailer’s stock worth $729,000 after purchasing an additional 26,811 shares during the last quarter. Quantinno Capital Management LP lifted its position in shares of Medifast by 15.1% during the first quarter. Quantinno Capital Management LP now owns 56,153 shares of the specialty retailer’s stock worth $572,000 after purchasing an additional 7,346 shares during the last quarter. State of Wyoming lifted its position in shares of Medifast by 19.8% during the first quarter. State of Wyoming now owns 6,646 shares of the specialty retailer’s stock worth $68,000 after purchasing an additional 1,097 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Medifast by 10.9% during the first quarter. Dimensional Fund Advisors LP now owns 361,762 shares of the specialty retailer’s stock worth $3,686,000 after purchasing an additional 35,522 shares during the last quarter. Finally, Corient Private Wealth LLC bought a new stake in shares of Medifast during the fourth quarter worth $139,000. 95.51% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Medifast

In other Medifast news, Director Scott Schlackman bought 2,500 shares of the firm’s stock in a transaction dated Monday, May 11th. The stock was acquired at an average cost of $12.53 per share, for a total transaction of $31,325.00. Following the completion of the transaction, the director owned 30,549 shares in the company, valued at $382,778.97. This trade represents a 8.91% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Daniel R. Chard bought 17,678 shares of the firm’s stock in a transaction dated Friday, March 20th. The shares were acquired at an average price of $10.11 per share, with a total value of $178,724.58. Following the completion of the transaction, the chief executive officer owned 17,678 shares of the company’s stock, valued at approximately $178,724.58. The trade was a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders have bought 22,678 shares of company stock valued at $241,675. Corporate insiders own 3.70% of the company’s stock.

About Medifast

Medifast, Inc (NYSE: MED) is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client’s weight‐loss journey.

Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight‐management solutions.